CD8A and neoplasm: AAPCs have been exploited as a versatile platform for cellular therapies including antigen-specific CD8+ T cells, antigen-specific CD4+ T cells, CAR-T cells, Treg cells, NK cells, etc. AAPCs facilitate the delivery of essential signals to selected subsets of T cells [125] and rapidly expand tumor-specific T cells [126].